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Abstract
Background: Medulloblastoma is the most common malignant brain tumor in children and can be divided in
different molecular subgroups. Patients whose tumor is classified as a Group 3 tumor have a dismal prognosis.
However only very few tumor models are available for this subgroup.
Methods: We established a robust orthotopic xenograft model with a cell line derived from the malignant pleural
effusions of a child suffering from a Group 3 medulloblastoma.
Results: Besides classical characteristics of this tumor subgroup, the cells display cancer stem cell characteristics
including neurosphere formation, multilineage differentiation, CD133/CD15 expression, high ALDH-activity and high
tumorigenicity in immunocompromised mice with xenografts exactly recapitulating the original tumor architecture.
Conclusions: This model using unmanipulated, human medulloblastoma cells will enable translational research,
specifically focused on Group 3 medulloblastoma.
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Background
Medulloblastoma is the most common malignant brain
tumor in childhood [1]. The current standard of care
consists of multimodal age- and stage-adapted therapy
including surgical resection, irradiation and chemother-
apy. The approach significantly increased survival rates
over the last decades, but a subset of tumors with a still
devastating prognosis remains. These aggressive tumors
do not respond even to high intensity treatment regi-
mens [2]. Indicators of poor prognosis are large cell/ana-
plastic (LCA) histology [3–6], metastasis [7, 8], MYC
amplification [3–5, 8–10], TP53 alteration [11, 12] and
gain of chromosome 17q [9].
Gene expression analysis clearly defines molecular
subgroups with distinct biological characteristics. These
subgroups differ in their cellular origins, activation path-
ways and clinical/pathological characteristics [13–17].
Therefore medulloblastoma cannot be considered as one
single disease entity. There is a consensus that four dif-
ferent main molecular subgroups of medulloblastoma
exist: WNT, SHH, Group 3 and Group 4 [18]. For WNT
and SHH the driving pathways are known and well-
validated mouse models are established [18–22]. For
Group 3 and 4 tumors data are more limited, also due
to the lack of appropriate animal models. As Group 3
tumors have the worst prognosis among the identified
subgroups, there is a clear need for reliable tumor
models. This subgroup of medulloblastoma almost only
occurs in infants and children, particularly in males [23,
24]. Furthermore, it is marked by an extremely high dis-
semination tendency into the cerebrospinal fluid (CSF).
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Genetic alterations are found frequently, such as gain of
chromosome 17q and amplification of the MYC onco-
gene. In fact, in most cases amplification of the MYC
oncogene seems to be restricted to this group and
associated with poor clinical outcome [18, 23, 24]. Two re-
cent studies focus on syngenic mouse models engineering
Myc-overexpressing cerebellar cells [25, 26]. Pei et al. in-
troduced Myc into CD133+ cells of the cerebellar white
matter and Kawauchi et al. into granule neuron precur-
sors. In combination with p53 blockade both models led
to the formation of highly aggressive medulloblastomas
recapitulating human MYC-driven Group 3 medulloblas-
toma. Furthermore Stearns et al. evaluated xenograft
models of the medulloblastoma cell lines DAOY and
UW228, demonstrating that Myc overexpression was re-
quired to achieve tumor engraftment of UW228 cells
which was linked to anaplastic histology [27]. Two other
groups also established murine medulloblastoma models
with anaplastic characteristics, but in these tumors over-
expression of MYCN is a key characteristic [28, 29].
The cancer stem cell hypothesis suggests that within
one tumor a hierarchy of tumor cells exist: most cancer-
ous cells will not have the propensity to create new tu-
mors by themselves, whereas the few tumor-initiating
cells are the founding cells of an arising tumor. These
undifferentiated self-renewing cells are the propagating
pool responsible for tumor growth [30]. Cancer stem
cells (CSC) seem to be a major cause for tumor aggres-
siveness and relapse because of their high radio- and
chemoresistance [31, 32]. Therefore studying this cell
population could be a reasonable and promising ap-
proach for the understanding of tumor pathogenesis and
for the development of new therapies [33, 34].
For medulloblastoma several lines of evidence support
the CSC hypothesis [33–36]. Although questions about
the frequency of such cells, their origin and the exact
phenotypical and functional characteristics remain. Ex-
perimentally the capacity to exactly recapitulate the ori-
ginal tumor architecture in xenograft models, with tumors
arising from very few cells, is a strong indicator of CSC
properties [37]. Clinically the role of these aggressive cells,
e.g. with regard to metastasis, is even less clear.
Here we describe a case of a Group 3 medulloblas-
toma with an unusual clinical occurrence of extracranial
metastasis of tumor cells displaying predominantly CSC
characteristics. When transplanted as an orthotopic
murine xenograft this anaplastic medulloblastoma dem-
onstrates many characteristics reported for CSC as well
as for the highly aggressive Group 3 medulloblastoma.
Methods
Clinical case
Diagnostics and treatment of the patient were conducted
at the University Hospital of Würzburg according to
HIT 2000 and HIT-Rez 2005 trial of the German Society
of Pediatric Oncology and Hematology. These thera-
peutic multi-center studies had been approved by the
local ethical committee of the University Hospital Würz-
burg and Bonn (No. 73/00 (Würzburg) for HIT 2000
and No. 105/05 (Bonn) for HIT-Rez 2005) and include
terms regarding the use of tumor material for additional
studies. The guardians provided written consent for par-
ticipation of their child on the clinical study. The pa-
tient’s parents consented in writing to the analysis of the
tumor cells based on an individual decision due to the
exceptional clinical course, which is in file along with
the medical case documentation. This written consent
includes extensive characterization, culture and storage
of the tumor cells and establishment of a stable tumor
cell line. It also includes genetic characterization and
genetic alteration (such as lentiviral transduction) and
use of the tumor cells in animal models.
Tumor cell isolation and cell culture
Tumor cells from the malignant pleural effusions were
isolated by performing a Ficoll gradient. Cells were dir-
ectly propagated using DMEM (GIBCO) supplemented
with 10 % foetal bovine serum (PAA), 40 U/ml penicillin
(PAA) and 40 μg/ml streptomycin (PAA) for 4 days.
After that time point cells were transferred into serum-
free DMEM/F12 (GIBCO) containing 20 ng/ml basic
fibroblast growth factor (bFGF), (PEPROTECH), 20 ng/ml
epidermal growth factor (EGF), (PEPROTECH), 2 % B-27
supplement (GIBCO), 1 % MEM Vitamins (GIBCO), 40
U/ml penicillin (PAA) and 40 μg/ml streptomycin (PAA)
and long-term cultured under that conditions. For differ-
entiation, cells were again cultured in serum-containing
medium.
Tumor cell lines
For comparative assays, we used the following tumor cell
lines: The glioblastoma cell lines R11 and R28 have been
described to have CSC characteristics and were kindly
provided by Drs. Beier D and Beier CP (University of
Regensburg, now Odense, Denmark). The melanoma cell
line FM88 was kindly provided by Dr. Becker C (now
University of Essen). MCF7 is a breast carcinoma cell
line, kindly provided by Dr. Wischhusen J (University
Hospital of Würzburg). U251 and U373 are glioma cell
lines, kindly provided by Dr. Hagemann (University Hos-
pital of Würzburg).
Proliferation assay
Single tumor cells from in serum-free medium cultured
neurospheres or from the adherent phase of in serum-
containing medium cultured cells were obtained by
mechanical dissociation or enzymatic detachment. Trip-
licates of viable cells were plated in 24 well microplates
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at densities of 2 × 105 cells/well and propagated in 1 ml/
well. After 3 days fresh medium was added. Either
serum-containing medium or serum-free medium was
used. Every day a triplicate of wells was counted to
examine cell proliferation.
Flow cytometry
Cells were mechanically dissociated to obtain single cell
suspensions. After centrifugation cells were resuspended
in CliniMACS PBS/EDTA buffer (Miltenyi Biotec) with
0,5 % human serum (PAA). Before staining with fluoro-
chrome conjugated antibodies, Fc receptors were blocked
with FcR Blocking Reagent (Miltenyi Biotec). Antibody
staining was conducted with CD133/1 and CD133/2
(Miltenyi Biotec, clones AC133 and 293C3) and anti-
CD15-antibody (BD, clone MMA) according to the manu-
facturer’s protocols. Acquisition was performed on a FACS
Canto II (BD Biosciences). Dead cells were excluded by 7-
AAD (BD Biosciences) staining. Expression of aldehyde
dehydrogenase (ALDH) was examined using the ALDE-
FLUOR kit (STEMCELL Technologies) according to the
manufacturer’s protocol.
Magnetic activated cell sorting
Cells were sorted for CD133/1 expression using the
CD133 MicroBead Kit (Miltenyi Biotec). First cells were
mechanically dissociated and centrifuged. After resus-
pension in 300 μl CliniMACS PBS/EDTA buffer with
0.5 % human serum, 100 μl FcR Blocking Reagent and
next 100 μl CD133/1 MicroBeads were added. Cells were
incubated for 30 min at 4 °C and another 5 min after
addition of 50 μl of CD133/2 (Miltenyi Biotec). Next
cells were washed and separated using MACS LS col-
umns (Miltenyi Biotec). To achieve higher purities two
additional consecutive column runs were performed.
Lentiviral transduction
Cells were lentivirally transduced with a vector encoding
firefly luciferase (FLuc) and enhanced green fluorescent
protein (eGFP) as described previously [38]. Transduced
cells were enriched by sorting for eGFP expression.
Animals and orthotopic xenotransplantation
Permission for animal experiments were obtained from
the institutional animal care committee for the Univer-
sity Hospital Würzburg. All animal experiments were
performed in accordance with national guidelines and
regulations and with approval of the district government.
Female NOD.CB17-Prkdcscid/J (NOD/SCID) mice were
purchased from The Jackson Laboratory and housed
under specific pathogen free conditions. Single cell sus-
pensions were prepared either by mechanical disruption
or enzymatical detachment, where necessary. Cell num-
bers were adjusted in culture medium by serial dilution,
calculated for an inoculation volume of 3 μl. Cells were
orthotopically injected into the brains of 10–13 week-
old anesthetized NOD/SCID mice using a stereotaxic
instrument (David Kopf Instruments) and a Hamilton
syringe with a 26 G needle (Hamilton Company), inject-
ing at defined coordinates: two injection sites were eval-
uated: for supratentorial inoculation cells were injected
in the dorsolateral thalamus, for infratentorial inocula-
tion cells were injected in the right cerebellum. Subse-
quently, mice were checked daily using bioluminescence
imaging (BLI). Survival was defined as the time from
transplantation until an early humane endpoint when
mice were sacrificed because they showed first symp-
toms of disease.
In vivo BLI
Mice were injected intraperitoneally with a mixture of
esketamine (80 mg/kg, Pfizer), xylazine (16 mg/kg, CP-
Pharma) and D-luciferin (300 mg/kg, Biosynth). 10 min
after injection animals were imaged using an IVIS
Spectrum imaging system as previously described (Cali-
per Life Sciences) [39]. Imaging data were analyzed with
Living Image 4.0 (Caliper-Xenogen) and Prism 5 soft-
ware (GraphPad).
Cytogenetic analysis
Cell cycle arrest was induced by Colcemid (GIBCO).
Cells were treated with 0.075 M KCl and fixed in 3:1
alcohol:acetic acid. For karyotyping cells were dried on
glass slides and then incubated in 500 μg/ml trypsin
(SERVA) for 20 s and subsequently stained in 5 %
Giemsa solution for 6 min. For FISH analysis the Vysis
LSI MYC/CEP 8 probes, the PathVysion HER-2 DNA
and the Vysis MYC Break Apart Rearrangement FISH
Probe Kits (Abbott Molecular) according to the manu-
facturer’s protocols were used: After FISH probes were
added, specimens were heat denaturated and incubated
at 37 °C over night for hybridization of FISH probes with
DNA. Specimens were then washed and mounted with
VECTASHIELD Mounting Medium with DAPI (Vector).
For visualization the Ikaros and Isis systems (MetaSys-
tems) were used.
Nanostring analysis
Nanostring analysis was performed on RNA extracted
from an early and late passage of the MB3W1 cells ac-
cording to the methods recently described [40]. Heat-
maps were created using the GenePattern software.
Histopathology and immunohistochemistry
Brains of sacrificed mice were immediately formaldehyde
(MERCK) fixed and paraffin (Leica Biosystems) embed-
ded. Specimens were sectioned at a thickness of 3 μm.
Histopathology was evaluated by staining sections with a
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standard Hematoxylin Eosin (HE) protocol. Cytospin
preparations were performed at 55 g for 5 min and
stained with Pappenheim or HE solutions.
For immunohistochemistry antigen retrieval was con-
ducted with heat induced epitope retrieval using citrate
buffer at pH 6.0 (almost all stainings) or with Tris/EDTA
buffer at pH 9.0 (CD133 staining). Incubation with the
following primary antibodies was performed over night
at 4 °C: ßIII-Tubulin (Abcam, ab18207; 1:500), CD99
(DAKO, clone 12E7; 1:200), CD133/1 (Miltenyi, clone
AC133; 1:40), GFAP (Millipore, AB5804; 1:6000), INI-1
(BD, clone 25/BAF47; 1:100), Ki-67 (dianova, M501;
1:80), Nestin (Millipore, clone 10C2 1:200), Olig2
(LINARIS, BHU0409, 1:100), p53 (DAKO, clone DO-7;
1:100), Synaptophysin (DAKO, clone SY38; 1:80) and
Vimentin (DAKO, clone V9; 1:4000). Immunodetection
was performed with the MultiLink HRP kit (BioGenex)
and DAB (Dako). Specific antigen recognition was
tested by using positive and negative controls.
For immunohistochemical analysis of cytospins the
APAAP method was used as a standard method. Briefly,
cells were spun onto glas slides and fixed with methanol-
acetone. After washing in TRIS-buffer, CD133/1 (Miltenyi,
clone AC133) was added onto the slides. Staining control
consisted of samples stained with the same procedure, but
omitting the primary antibody. After 30 min of incubation
at room temperature (RT), slides were washed and incu-
bated with the secondary reagent (rabbit-anti-mouse-anti-
body, DAKO) for 30 min at RT. After additional washing
the APAAP-immunocomplex (tertiary reagent, DAKO)
was added for 30 min at, followed by additional wash-
steps and incubation with APAAP-reaction solution for
30 min at RT (on a shaker). After additional washing
steps, slides were incubated with Haemalaun solution for
2 min, before the slides were finally washed and covered
with glass cover slips.
Results
Clinical case
A 22-month-old boy presented with rapidly progressive
gait disorder. Magnetic resonance imaging (MRI) re-
vealed a cerebellar tumor arising from the bottom of the
4th ventricle. Cytology from the CSF was positive for
malignant cells. Immediate tumor resection was per-
formed and the diagnosis was confirmed as anaplastic
medulloblastoma (Fig. 1a and b). Atypical teratoid/rhab-
doid tumor (AT/RT) and Ewing sarcoma (EWS) was
excluded based on maintained INI1 expression and
absence of the EWS/FLI1 translocation and CD99 ex-
pression. Reference pathology (Prof. T. Pietsch, Bonn)
confirmed the histopathological diagnosis and deter-
mined MYC amplification in the original tumor sample.
Postoperative MRI showed no residual tumor, but signs
of meningeosis. In the days following surgery the child
developed intracranial hypertension requiring liquor
drainage and a ventriculoperitoneal shunt. Three weeks
after resection the boy started to developed signs of
brain stem incarceration with brain stem areflexia. MRI
revealed a massive increase of the leptomeningeal spread
with compression of the brain stem (Fig. 1a, right pic-
ture). Emergency cranial irradiation was initiated (ini-
tially 3 Gy/day, followed by 2 Gy/day) and subsequently
extended to the entire neural axis (total dose: tumor re-
gion 53 Gy, cranium 29 Gy, spine 32 Gy). Irradiation-
induced partial regression of the leptomeningeal spread
was maintained by chemotherapy including lomustine,
vincristine and cisplatin (later cyclophosphamide) ac-
cording to the german treatment optimization study
HIT 2000. Nine months after diagnosis the tumor re-
lapsed in the former tumor bed and next to the left ven-
tricle. Moreover the leptomeningeal spread progressed.
The chemotherapy regimen was adapted to the HIT-
REZ 2005 study and etoposide was now administered
intraventricularly. However tumor control was not
achieved. Shortly before his death, 10 months after the
initial diagnosis, the boy developed pleural effusions,
initially on one side and then bilaterally. Pleural effu-
sions required pleurocentesis revealing predominantly
malignant cells. From these pleural effusions, the cell
line named MB3W1 (for medulloblastoma-Group 3-
Würzburg 1) was derived.
MB3W1 cells phenotypically and functionally display
characteristics associated with CSC
After isolation of MB3W1 cells via Ficoll gradient and
brief culture (4 days) in serum-containing medium, cells
were analyzed by flow cytometry. We stained the cells
for several markers associated with CSC [41]. Interest-
ingly MB3W1 cells strongly expressed CD133 and CD15
(Fig. 2a), both of which are markers associated with CSC
[37, 42–46]. Expression of these markers was high, when
compared to other cell lines – from other tumor entities –
with a documented CSC activity (glioblastoma: R28 and
R11 [41]; breast cancer: MCF7 [47]; Additional file 1:
Figure S1). Considering the phenotype, we asked whether
cell growth could be maintained under culture conditions
propagating neural stem cells. Culture in serum-free
medium containing bFGF and EGF promotes the growth
of undifferentiated stem cells that form neurospheres and
show self-renewal and exponential long-term proliferation
[42, 48, 49]. In fact, when MB3W1 cells were cultured
under these conditions, they formed neurospheres (Fig. 2b)
and proliferated rapidly (Fig. 2c). Long-term cultures were
easily established. Cells could be passaged more than 30
times without showing changes in their growth character-
istics. Flow cytometry analysis for CD133 after 30 passages
showed no significant changes compared to the initial
staining pattern (Fig. 2d). When cells were cultured in
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serum-containing medium, growth characteristics chan-
ged: cells became plastic adherent and proliferation de-
creased. However, neurosphere formation still continued.
These neurosphere-building cells were the proliferating
part while the adherent fraction basically did not prolifer-
ate (Fig. 2b and c).
We also analyzed ALDH activity in this cell line as we
suspected CSC properties. Besides certain cell surface
markers, ALDH activity is considered as a functional
hallmark of CSC [50, 51]. MB3W1 cells displayed strong
ALDH activity, which by far exceeded the activity of the
previously described glioblastoma CSC lines R28 and
R11 [41] (Fig. 2e). These findings indicate, that the ma-
jority of the primary cells from the pleural effusions
show characteristics described for CSC.
MB3W1 cells show aggressive orthotopic tumor
formation in immunocompromised mice
CSC are highly tumorigenic when transplanted into im-
munocompromised mice. To directly examine this fea-
ture, MB3W1 cells were transduced with a lentiviral
vector encoding FLuc and eGFP (data available on re-
quest). Transduction did not alter growth characteristics
nor did it change the cells phenotype. When 5 × 104 cells
were injected either infra- or supratentorially into NOD/
SCID mice, 100 % of tumors engrafted and grew immedi-
ately after inoculation (Fig. 3a and b). Survival was not sig-
nificantly different, when implanting unmodified tumor
cells. We next asked, whether growth differed, when
tumor cells had been cultured in serum-containing
medium, leading to a mixed population of adherent cells
and small neurospheres in vitro. Tumor cells were
injected supratentorially using titrated cell numbers ran-
ging from as few as 5000 up to 5 × 105 cells. Under either
condition and with as few as 5000 cells per injection,
tumor growth rates were 100 %. If tumor cells had been
partially differentiated prior to transplantation using
serum-containing medium (12 days), tumor growth slo-
wed down, but still all animals developed tumors (Fig. 3c).
We next asked, whether in vivo growth characteristics
differed when separating out CD133+ from CD133−
tumor cells. Separation was performed with magnetic
beads, resulting in purities of 88.4 % for the CD133+ and
95.2 % for the CD133− cell fraction. Both CD133+ as
well as CD133− cells remained highly proliferative with
rapid tumor growth even at numbers as low as 5000
cells per injection, confirming that CD133 alone does
not sufficiently define tumor initiating cells (Fig. 3d).
Xenotransplanted MB3W1 cells exactly recapitulate the
original tumor
One of the key criteria of CSC is that xenotransplants
exactly recapitulate the histopathological characteristics
of the original tumor [37]. We therefore compared xeno-
transplanted tumors with the histology of the patient’s
primary tumor. Mouse xenografts exactly matched the
morphological and biological characteristics of the ori-
ginal tumor. Xenotransplants showed anaplastic cell
morphology consisting of tumor cells with marked
nuclear polymorphism, typical nuclear angulation or
moulding and frequent cell wrapping phenomena. Apop-
tosis (even whole areas of apoptotic cells) as well as ne-
crosis were observed frequently. Abundant mitosis and a
high Ki-67 staining index (50–60 %) reflected the high
proliferation rate of MB3W1 cells (Fig. 4). When we
examined tumors for their differentiation we found
MB3W1 cells immunoreactive for markers known to be
expressed by stem/progenitor cells (like CD133 and Nes-
tin) [52, 53] and for markers associated with neuronal
(like Synaptophysin and ßIII-Tubulin) [54, 55], oligo-
dendroglial (like Olig2) [56, 57] or immature astrocytic
differentiation (like Vimentin) [58] (Fig. 4). A mature
astrocytic differentiation of tumor cells (indicated by
GFAP) [59] could not be detected. Thus the experimen-
tal MB3W1 tumors match the original tumor in many
Fig. 1 Illustration of the clinical case. a. Sagittal cranial MRI of the 22-month-old boy showing the initial tumor in the 4th ventricle (left, single
arrow) and signs of massive meningeosis 3 weeks later (right, multiple arrows). b. HE staining of the initial tumor showing typical anaplastic
morphology of the tumor cells. Insert: medulloblastoma cells from the CSF (Pappenheim-staining)
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histological and immunohistochemical features. Broad
expression of lineage markers supports the potential of
multilineage differentiation as typically observed in CSC.
Of note, MB3W1 cells also seem to reflect the invasive
and spreading behavior of the patient’s tumor. At the
humane endpoint, when tumors had grown to the max-
imal tolerable size, dissemination into the subarachnoid
space could routinely be detected (Fig. 5a–c). Tumor
cells present in the CSF displayed the same high prolifer-
ation as the cells that engrafted in the brain (proved by
Ki-67 staining). Disseminated cells were also highly inva-
sive. Cells invaded from the brain surface and from
Virchow-Robin spaces into the brain (Fig. 5d and e) gen-
erating metastases even at sites far away from the initial
inoculation point. Although technically there is a chance
of artificial contamination of the CSF during the inocu-
lation process, we believe that metastasis is rather due to
the highly malignant characteristics of these tumor cells:
we never detected such aggressive behavior when using
other tumor cells. Furthermore leptomeningeal spread
Fig. 2 Characteristics of medulloblastoma cells recovered from the pleural effusions after progression of disease. a. Representative flow cytometry
plots outlining the expression of CD133 and CD15 in MB3W1 cells. b. Light-microscopy of MB3W1 cells in culture in serum-free medium showing
sphere forming growth (left) and partly adherent growth in serum-containing medium (right). c. Growth characteristics of MB3W1 cells grown in
serum-free medium (left, purple columns), compared to growth in serum-containing medium (right, light blue columns = adherent fraction, dark
blue columns = spheroid fraction). d. Expression of CD133 on cells grown as spheres in serum-free medium at in vitro passage 1 (blue full line)
and passage 30 (blue broken line). Black line = isotype control. e. ALDH expression as measured by substrate conversion using the ALDEFLUOR
assay. Different cell lines were incubated with ALDH-substrate either without (green lines) or with a specific enzyme inhibitor to block ALDH-activity
(black lines). The degree of fluorescence correlates with ALDH-activity. R28 and R11 are glioblastoma cell lines recently characterized as cells with CSC
activity. U251 is a glioblastoma cell line with no known CSC activity
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was an event occurring in a late stage of tumor progres-
sion, whereas mice sacrificed at earlier time points
(1–2 weeks after transplantation) did not show any
metastasis.
Original pleural carcinosis showed a similar pattern of
CD133+ as cultivated MB3W1 cells
Extracranial metastasis of medulloblastoma, especially
with intensified chemotherapy, is a relatively rare event
[60]. In our case, cultivated tumor cells highly expressed
CD133. Thus we asked whether this expression had oc-
curred due to selection in vitro, or whether there had
been a biologic enrichment of such undifferentiated cells
during the course of disease progression. Enrichment
during the 4 day culture prior to the first analysis by
flow cytometry seems highly unlikely. More importantly
immunohistochemistry of cytospins obtained from cells
directly isolated from the pleural effusions showed a
similar pattern of CD133 expression compared to the
cultured tumor cells. In contrast, staining of the CSF
cytospins, obtained at the time point of the initial diag-
nosis, revealed plenty of tumor cells, but CD133
expression was low (Fig. 6). This suggests that CD133+
cells had likely been the driving force for generating ex-
tracranial metastasis, emphasizing the highly aggressive
and self-renewing characteristics of these cells.
MB3W1 cells show properties associated with Group 3
medulloblastoma
Among the recently identified molecular subgroups,
Group 3 medulloblastoma have the most aggressive
tumor biology. These tumors often exhibit features
known to be associated with poor clinical outcome such
as LCA histology, high dissemination tendency, gain of
chromosome 17q and MYC amplification [5, 9, 18, 23,
24]. These are the same features observed in our pa-
tient’s tumor. Aberration of the MYC oncogene is one of
the key molecular pathways in Group 3 medulloblas-
toma [25]: MYC can induce proliferation as well as
apoptosis [61]. Because MYC induced apoptosis often
depends on TP53 function [62], alterations of TP53 can
compensate the apoptotic effect of MYC leading to en-
hanced proliferation of cancer cells [25]. Indeed in
MB3W1 cells MYC was uniformly amplified and also
Fig. 3 In vivo growth characteristics of MB3W1. a. 5 × 104 luciferase-transduced MB3W1 cells were xenografted either infra- (open circles) or supra-
tentorially (closed circles), and tumor growth was monitored by BLI. b. Survival curves after infra- (pink, n = 6) versus supratentorial inoculation
(blue, n = 5; one animal lost during surgery (censored)); grey: untreated controls, surgery only (n = 2). c. Survival curves of mice inoculated with
untransduced tumor cells: comparison of MB3W1 cells previously grown in different culture conditions: supratentorial inoculation of cells previ-
ously grown as spheres in serum-free medium (pink curves, n = 5) and compared to inoculation of cells previously grown in serum-containing
medium – cells were only derived from the non-proliferative adherent fraction - (blue curves, n = 5). Circles: 5 × 105 cells, squares: 5 × 104 cells, tri-
angles: 5 × 103 cells. d. Growth characteristics of CD133+ (closed triangles, n = 5) and CD133− (open triangles, n = 5) MB3W1 cells after supratentorial
inoculation of 5000 tumor cells
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immunohistochemistry showed p53 accumulation (Fig. 7a).
Classic karyotyping (not shown) and FISH revealed a
male, tetraploid chromosomal pattern with an unbalanced
gain of chromosome 17q (Fig. 7a). All of these characteris-
tics are often observed in Group 3 tumors [24, 63].
Furthermore using nanostring analysis of a set of 22
genes, which has been described recently to accurately
define the molecular subgroups [40], we clearly con-
firmed that these tumor cells belong to the subgroup 3
(Fig. 7b). Comparative analysis of early and late passages
of the cells showed little variation of gene expression, thus
indicating a relatively stable gene expression pattern.
Discussion
We here established a xenograft model for anaplastic
medulloblastoma with a molecular Group 3 signature,
which clinically has a very poor prognosis [18]. There-
fore there is a clear need for additional animal models to
study this tumor subgroup [64]. Only recently two
groups established syngenic mouse models by genetically
interfering with the MYC and TP53 pathways, that
mimic Group 3 characteristics. Pei et al. and Kawauchi
et al. both introduced Myc into murine cerebellar cells
by genetic engineering, which, in combination with p53
blockade (either by introducing dominant negative p53
into CD133+ cells of the cerebellar white matter or by
using Trp53 null granule neuron precursors) led to the
formation of medulloblastomas resembling the Group 3
subtype [25, 26]. Our model is complementary to this
work, as it recapitulates the orthotopic growth of highly
aggressive human medulloblastoma without additional
genetic engineering. The only modification of the tumor
cells has been transduction with FLuc and eGFP for bet-
ter monitoring. This modification does not change the
biologic behavior of the cells, as in vitro growth (not
shown) and survival of mice were identical. Milde et al.
recently described a human Group 3 cell line, HD-
MB03, focusing on the impact of HDAC-inhibitors as a
potential treatment option [65]. In an evaluation of
established long-term cultured cell lines, Shu et al. re-
ported on good in vivo growth characteristics of D283-
MED, a medulloblastoma cell line, that has some charac-
teristics, albeit not complete congruency, of a Group 3
tumor cell line [66, 67]. Mastronuzzi et al. recently
Fig. 4 Immunohistological evaluation of the original tumor and xenografted infratentorial tumor. Selected markers are shown in comparison. For
some markers, there was not sufficient material left from the primary tumor. All specimens were formaldehyde fixed and paraffin embedded prior
to histopathological evaluation
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Fig. 5 Xenografts show signs of metastasis. a. Macroscopically subarachnoidal tumor dissemination is seen frequently at tumor progression and
b. tumor cells can then constantly be found in the CSF (HE stained gross section). c. Xenograft cytospin of subarachnoidal disseminated tumor
cells at the humane endpoint reveal blue-cell tumor cells with for LCA histology typical cell wrapping (arrow). d. Histology (HE-staining) indicates
aggressive, infiltrative behavior with xenografted tumor cells invading from the brain surface (arrow head) and the Virchow-Robin spaces (arrows).
e. Vimentin-staining showing tumor cells with pseudopodia reaching from the brain surface into the brain tissue
Fig. 6 Evaluation of CD133 expression in MB3W1 cells directly after cell isolation and during cell culture. Cytospins from different cell preparations
were evaluated for CD133. Preferred expression of CD133 on cells directly derived from the pleural effusions (lower left) and on cultivated MB3W1
cells at day 4 after isolation (lower right). In comparison cytospins from the CSF at diagnosis showed little (if any) staining for CD133 (upper right).
(Upper left: staining control)
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reported on a similar case of anaplastic medulloblastoma
with metastasis to the scalp, also displaying some fea-
tures of CSC in their in vitro evaluation [68]. Taken to-
gether, these unmodified human tumor models will
advance the field of medulloblastoma research especially
with respect to the dismal Group 3 tumors: a compre-
hensive analysis of the available Group 3 cell lines, HD-
MB03 and MB3W1, plus potentially D283-Med, may
lead to urgently needed new treatment strategies for this
tumor type.
Further studies are necessary to determine whether
this tumor model can also be used to study the mecha-
nisms leading to metastasis: the data presented here sug-
gest that metastasis into the CSF is characteristic for
these cells once the tumor reaches a certain size.
However there remains a slight chance of a potential
contamination during the injection process. On the
other hand, the dynamics of metastasis and our com-
parison to other transplanted tumor models strongly
argue for spontaneous dissemination of the tumor
cells. If so, this model will be extremely valuable to
assess the effect of drugs targeting exactly this
process of dissemination or to analyze the pathways
leading to this malignant spreading.
What is the originating cell of MB3W1 cells? Much is
known about the cells of origin and the driving pathways
of WNT and SHH medulloblastomas, but Group 3 tu-
mors are less well characterized [18–22]. Apparently
cells of different brain compartments could lead to a
Group 3 medulloblastoma as suggested by the two re-
cently published murine models. Importantly, MB3W1
cells also display several characteristics of CSC, as de-
scribed earlier for many tumor types [69]. The fact that
xenotransplanted MB3W1 cells engrafted to 100 % with
tumors exactly recapitulating the original tumor archi-
tecture, display functional characteristics such as high
ALDH activity, neurosphere formation and exponential
long-term proliferation all argue for stem-cell like prop-
erties [42, 48–51]. The expression of markers such as
CD133 and CD15 also is suggestive for stem-cell like
properties, although CD133 expression alone does not
define this distinct population. This is in line with work
Fig. 7 MB3W1 cells comprise a faithful Group 3 model. a. Upper panel: FISH analysis of MB3W1 cells revealed a clear amplification of the MYC
oncogene (green signal) as a hallmark of Group 3 tumors (in red: CEP8). Middle panel: FISH on chromosome 17 shows (consistent with the
patient’s karyogram) tetraploidy of the ERBB2 gen (red signal) and an unbalanced gain of chromosome 17q (green signal of the chromosome
enumeration probe 17p11.1-17q11.1). Lower panel: Immunohistochemical staining of xenotransplanted tumor specimen revealing accumulation
of p53 protein. b. Heatmap, illustrating analysis of a set of 22 marker genes previously validated for MB sub-grouping. Strong clustering of genes
regulated in Group 3 MB is observed. No significant differences in gene expression were detected in RNA derived from early passages (<5 passages) or
late passages (>20 passages)
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from different groups, indicating that CD133− tumor
cells may also have CSC capacities [41, 44].
Extracranial metastasis in medulloblastoma is a rela-
tively rare event. In the aforementioned case report, me-
dulloblastoma metastasis in the scalp was observed and
these cells also contained features of CSC [68]. The in-
crease in CD133+ cells in in the pleural effusion in our
patient, as well as the detection of CD133+ cells in the
metastasis of this other report, may argue for a role of
stem cell activity in the pathology of metastasis. It is un-
likely, that the ventriculoperitoneal shunt facilitated the
spread in our patient, as, despite pleural effusions, there
was no documented peritoneal spread. As this is a singu-
lar case, we cannot determine whether CD133+ expres-
sion (and CSC-capacities) is the cause for progression
and pleural spread or just coincidental. However the en-
richment in the pleural effusions is indicative of bio-
logically aggressive behavior of cells with this phenotype.
Analysis in larger patient cohorts is necessary to poten-
tially link this phenotype to clinical outcome.
Thus we conclude that the cells from which the
MB3W1 cell line originated must have had the capacity
to: 1) withstand chemo- and radiotherapy, 2) retain the
molecular/histochemical characteristics as a highly ag-
gressive, tumor initiating cell and 3) may have selectively
crossed the blood-brain barrier, albeit in the context of a
heavily pretreated patient, to disseminate to the pleura.
Conclusions
The high percentage of cells with CSC characteristics
within this cell line, which emerged after a natural selec-
tion process of extracranial metastasis, is remarkable
and provides a unique tool for medulloblastoma re-
search. We believe that this tumor model will be ex-
tremely valuable to study the aggressive biological
behavior of Group 3 medulloblastoma, - with a focused
approach to CSC, as well as to explore possible thera-
peutic interventions. MB3W1 cells will be made avail-
able upon request (to Wölfl M or Schlegel PG).
Consent
Written informed consent was obtained from the par-
ents of the patient for publication of this case report and
any accompanying images. A copy of the written consent
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Additional file
Additional file 1: Figure S1. Phenotypical comparison of MB3W1 to
other tumor cell lines. (JPEG 2532 kb)
Abbreviations
ALDH: Aldehyde dehydrogenase; AT/RT: Atypical teratoid/rhabdoid tumor;
bFGF: Basic fibroblast growth factor; BLI: Bioluminescence imaging;
CSC: Cancer stem cells; CSF: Cerebrospinal fluid; DNA: Deoxyribonucleic acid;
EGF: Epidermal growth factor; eGFP: Enhanced green fluorescent protein;
EWS: Ewing sarcoma; FLuc: Firefly luciferase; HE: Hematoxylin eosin;
LCA: Large cell anaplastic; MB3W1: Medulloblastoma Group 3, Würzburg 1
cell line; MRI: Magnetic resonance imaging; RNA: Ribonucleic acid; RT: Room
temperature; SHH: Sonic hedge-hog; WNT: Wingless/Int-1.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SD, SSch, SD, SR, AB, CMM, AR, ME, GHV, DP, PGS and MW designed,
performed and analyzed in vitro and in vivo experiments. VR, MDT and MR
performed the nanostring analysis. FD, SR, AOvB, JK and TS were crucial in
preserving tumor tissue. FD, SR, AOvB, TS, JK and PGS were closely involved
with the care for this patient. SD and MW wrote the manuscript. All authors
read the manuscript and contributed to the final version.
Acknowledgements
We would like to thank the patient’s parents for allowing the work with
these tumor cells. This publication was funded by the German Research
Foundation (DFG) and the University of Würzburg in the funding program
Open Access Publishing.
Author details
1University Children’s Hospital, Pediatric Oncology, Hematology and Stem
Cell Transplantation, University of Würzburg, Würzburg, Germany.
2Department of Surgery II, University of Würzburg, Würzburg, Germany.
3Interdisciplinary Center for Clinical Research Laboratory (IZKF Würzburg),
Department of Internal Medicine II, University of Würzburg, Würzburg,
Germany. 4Department of Pediatric Oncology, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany. 5Department of Pediatrics and
Adolescent Medicine, Division of Pediatric Hematology and Oncology,
University Hospital of Geneva, Geneva, Switzerland. 6Department of
Neurosurgery, University of Würzburg, Würzburg, Germany. 7Department of
Pediatric Oncology, Hematology and Clinical Immunology / Department of
Neuropathology, Heinrich Heine University, Düsseldorf, Germany. 8Institute of
Pathology, University of Würzburg, Würzburg, Germany. 9Division of
Neurosurgery, Arthur and Sonia Labatt Brain Tumor Research Centre, Hospital
for Sick Children, Toronto, Canada. 10Comprehensive Cancer Center
Mainfranken, University of Würzburg, Würzburg, Germany.
Received: 25 May 2015 Accepted: 14 February 2016
References
1. Rickert CH, Paulus W. Epidemiology of central nervous system tumors in
childhood and adolescence based on the new WHO classification. Childs
Nerv Syst. 2001;17(9):503–11.
2. Pizer BL, Clifford SC. The potential impact of tumour biology on improved
clinical practice for medulloblastoma: progress towards biologically driven
clinical trials. Br J Neurosurg. 2009;23(4):364–75.
3. Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, et al.
Histopathological and molecular prognostic markers in medulloblastoma: c-
myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol. 2004;63(5):441–9.
4. von Hoff K, Hartmann W, von Bueren AO, Gerber NU, Grotzer MA, Pietsch T,
et al. Large cell/anaplastic medulloblastoma: outcome according to myc
status, histopathological, and clinical risk factors. Pediatr Blood Cancer. 2010;
54(3):369–76.
5. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, et al.
Definition of disease-risk stratification groups in childhood medulloblastoma
using combined clinical, pathologic, and molecular variables. J Clin Oncol
Off J Am Soc Clin Oncol. 2011;29(11):1400–7.
6. Massimino M, Antonelli M, Gandola L, Miceli R, Pollo B, Biassoni V, et al.
Histological variants of medulloblastoma are the most powerful clinical
prognostic indicators. Pediatr Blood Cancer. 2013;60(2):210–6.
7. Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, et al.
Metastasis stage, adjuvant treatment, and residual tumor are prognostic
factors for medulloblastoma in children: conclusions from the Children’s
Cancer Group 921 randomized phase III study. J Clin Oncol Off J Am Soc
Clin Oncol. 1999;17(3):832–45.
Dietl et al. BMC Cancer  (2016) 16:115 Page 11 of 13
8. Grotzer MA, von Hoff K, von Bueren AO, Shalaby T, Hartmann W, Warmuth-Metz
M, et al. Which clinical and biological tumor markers proved predictive in the
prospective multicenter trial HIT’91–implications for investigating childhood
medulloblastoma. Klin Padiatr. 2007;219(6):312–7.
9. Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, et al.
Outcome prediction in pediatric medulloblastoma based on DNA copy-
number aberrations of chromosomes 6q and 17q and the MYC and MYCN
loci. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27(10):1627–36.
10. Ryan SL, Schwalbe EC, Cole M, Lu Y, Lusher ME, Megahed H, et al. MYC
family amplification and clinical risk-factors interact to predict an extremely
poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;
123(4):501–13.
11. Ray A, Ho M, Ma J, Parkes RK, Mainprize TG, Ueda S, et al. A clinicobiological model
predicting survival in medulloblastoma. Clin Cancer Res. 2004;10(22):7613–20.
12. Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN, et al. Universal
poor survival in children with medulloblastoma harboring somatic TP53
mutations. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(8):1345–50.
13. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, et al.
Genomics identifies medulloblastoma subgroups that are enriched for
specific genetic alterations. J Clin Oncol Off J Am Soc Clin Oncol. 2006;
24(12):1924–31.
14. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, et al. Integrated
genomics identifies five medulloblastoma subtypes with distinct genetic
profiles, pathway signatures and clinicopathological features. PLoS One.
2008;3(8):e3088.
15. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, et al.
Integrative genomic analysis of medulloblastoma identifies a molecular
subgroup that drives poor clinical outcome. J Clin Oncol Off J Am Soc Clin
Oncol. 2011;29(11):1424–30.
16. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al.
Medulloblastoma comprises four distinct molecular variants. J Clin Oncol Off
J Am Soc Clin Oncol. 2011;29(11):1408–14.
17. Remke M, Hielscher T, Northcott PA, Witt H, Ryzhova M, Wittmann A, et al.
Adult medulloblastoma comprises three major molecular variants. J Clin
Oncol Off J Am Soc Clin Oncol. 2011;29(19):2717–23.
18. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al.
Molecular subgroups of medulloblastoma: the current consensus. Acta
Neuropathol. 2012;123(4):465–72.
19. Schuller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, et al.
Acquisition of granule neuron precursor identity is a critical
determinant of progenitor cell competence to form Shh-induced
medulloblastoma. Cancer Cell. 2008;14(2):123–34.
20. Gilbertson RJ, Ellison DW. The origins of medulloblastoma subtypes. Annu
Rev Pathol. 2008;3:341–65.
21. Yang ZJ, Ellis T, Markant SL, Read TA, Kessler JD, Bourboulas M, et al.
Medulloblastoma can be initiated by deletion of Patched in lineage-
restricted progenitors or stem cells. Cancer Cell. 2008;14(2):135–45.
22. Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, et al.
Subtypes of medulloblastoma have distinct developmental origins. Nature.
2010;468(7327):1095–9.
23. Northcott PA, Korshunov A, Pfister SM, Taylor MD. The clinical implications
of medulloblastoma subgroups. Nat Rev Neurol. 2012;8(6):340–51.
24. Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, et
al. Molecular subgroups of medulloblastoma: an international meta-analysis
of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group
3, and Group 4 medulloblastomas. Acta Neuropathol. 2012;123(4):473–84.
25. Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, et al. An animal
model of MYC-driven medulloblastoma. Cancer Cell. 2012;21(2):155–67.
26. Kawauchi D, Robinson G, Uziel T, Gibson P, Rehg J, Gao C, et al. A mouse
model of the most aggressive subgroup of human medulloblastoma.
Cancer Cell. 2012;21(2):168–80.
27. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG.
c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res.
2006;66(2):673–81.
28. Shakhova O, Leung C, van Montfort E, Berns A, Marino S. Lack of Rb and
p53 delays cerebellar development and predisposes to large cell anaplastic
medulloblastoma through amplification of N-Myc and Ptch2. Cancer Res.
2006;66(10):5190–200.
29. Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg
DD, et al. Pleiotropic role for MYCN in medulloblastoma. Genes Dev.
2010;24(10):1059–72.
30. Vescovi AL, Galli R, Reynolds BA. Brain tumour stem cells. Nat Rev Cancer.
2006;6(6):425–36.
31. Garvalov BK, Acker T. Cancer stem cells: a new framework for the design of
tumor therapies. J Mol Med. 2011;89(2):95–107.
32. Friedman GK, Gillespie GY. Cancer Stem Cells and Pediatric Solid Tumors.
Cancer. 2011;3(1):298–318.
33. Vanner RJ, Remke M, Gallo M, Selvadurai HJ, Coutinho F, Lee L, et al.
Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic
hedgehog subgroup medulloblastoma. Cancer Cell. 2014;26(1):33–47.
34. Manoranjan B, Venugopal C, McFarlane N, Doble BW, Dunn SE,
Scheinemann K, et al. Medulloblastoma stem cells: modeling tumor
heterogeneity. Cancer Lett. 2013;338(1):23–31.
35. Eberhart CG. In search of the medulloblast: neural stem cells and embryonal
brain tumors. Neurosurg Clin N Am. 2007;18(1):59–69. viii-ix.
36. Wang J, Wechsler-Reya RJ. The role of stem cells and progenitors in the
genesis of medulloblastoma. Exp Neurol. 2014;260:69–73.
37. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification
of human brain tumour initiating cells. Nature. 2004;432(7015):396–401.
38. Thalheimer A, Korb D, Bonicke L, Wiegering A, Muhling B, Schneider M, et
al. Noninvasive visualization of tumor growth in a human colorectal liver
metastases xenograft model using bioluminescence in vivo imaging. J Surg
Res. 2013;185(1):143–51.
39. Riedel SS, Mottok A, Brede C, Bauerlein CA, Jordan Garrote AL, Ritz M, et al.
Non-invasive imaging provides spatiotemporal information on disease
progression and response to therapy in a murine model of multiple
myeloma. PLoS One. 2012;7(12):e52398.
40. Northcott PA, Shih DJ, Remke M, Cho YJ, Kool M, Hawkins C, et al. Rapid,
reliable, and reproducible molecular sub-grouping of clinical
medulloblastoma samples. Acta Neuropathol. 2012;123(4):615–26.
41. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, et al.
CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential
growth characteristics and molecular profiles. Cancer Res. 2007;67(9):4010–5.
42. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al.
Identification of a cancer stem cell in human brain tumors. Cancer Res.
2003;63(18):5821–8.
43. Mao XG, Zhang X, Xue XY, Guo G, Wang P, Zhang W, et al. Brain Tumor
Stem-Like Cells Identified by Neural Stem Cell Marker CD15. Transl Oncol.
2009;2(4):247–57.
44. Read TA, Fogarty MP, Markant SL, McLendon RE, Wei Z, Ellison DW, et al.
Identification of CD15 as a marker for tumor-propagating cells in a mouse
model of medulloblastoma. Cancer Cell. 2009;15(2):135–47.
45. Son MJ, Woolard K, Nam DH, Lee J, Fine HA. SSEA-1 is an enrichment
marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell.
2009;4(5):440–52.
46. Ward RJ, Lee L, Graham K, Satkunendran T, Yoshikawa K, Ling E, et al.
Multipotent CD15+ cancer stem cells in patched-1-deficient mouse
medulloblastoma. Cancer Res. 2009;69(11):4682–90.
47. Comsa S, Cimpean AM, Raica M. The Story of MCF-7 Breast Cancer Cell Line:
40 years of Experience in Research. Anticancer Res. 2015;35(6):3147–54.
48. Reynolds BA, Weiss S. Clonal and population analyses demonstrate that an
EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev
Biol. 1996;175(1):1–13.
49. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al. Isolation
and characterization of tumorigenic, stem-like neural precursors from
human glioblastoma. Cancer Res. 2004;64(19):7011–21.
50. Alison MR, Guppy NJ, Lim SM, Nicholson LJ. Finding cancer stem cells: are
aldehyde dehydrogenases fit for purpose? J Pathol. 2010;222(4):335–44.
51. Rasper M, Schafer A, Piontek G, Teufel J, Brockhoff G, Ringel F, et al.
Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor
stem cell capacity. Neuro-Oncology. 2010;12(10):1024–33.
52. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, et al. Direct
isolation of human central nervous system stem cells. Proc Natl Acad Sci
U S A. 2000;97(26):14720–5.
53. Lendahl U, Zimmerman LB, McKay RD. CNS stem cells express a new class
of intermediate filament protein. Cell. 1990;60(4):585–95.
54. Schwechheimer K, Wiedenmann B, Franke WW. Synaptophysin: a reliable
marker for medulloblastomas. Virchows Arch A Pathol Anat Histol.
1987;411(1):53–9.
55. Katsetos CD, Legido A, Perentes E, Mork SJ. Class III beta-tubulin isotype: a key
cytoskeletal protein at the crossroads of developmental neurobiology and tumor
neuropathology. J Child Neurol. 2003;18(12):851–66. discussion 867.
Dietl et al. BMC Cancer  (2016) 16:115 Page 12 of 13
56. Ligon KL, Alberta JA, Kho AT, Weiss J, Kwaan MR, Nutt CL, et al. The
oligodendroglial lineage marker OLIG2 is universally expressed in diffuse
gliomas. J Neuropathol Exp Neurol. 2004;63(5):499–509.
57. Jakovcevski I, Zecevic N. Olig transcription factors are expressed in
oligodendrocyte and neuronal cells in human fetal CNS. J Neurosci.
2005;25(44):10064–73.
58. Schnitzer J, Franke WW, Schachner M. Immunocytochemical demonstration
of vimentin in astrocytes and ependymal cells of developing and adult
mouse nervous system. J Cell Biol. 1981;90(2):435–47.
59. Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one
years (1969-2000). Neurochem Res. 2000;25(9-10):1439–51.
60. Rickert CH. Extraneural metastases of paediatric brain tumours. Acta
Neuropathol. 2003;105(4):309–27.
61. Pelengaris S, Rudolph B, Littlewood T. Action of Myc in vivo - proliferation
and apoptosis. Curr Opin Genet Dev. 2000;10(1):100–5.
62. Hermeking H, Eick D. Mediation of c-Myc-induced apoptosis by p53.
Science. 1994;265(5181):2091–3.
63. Jones DT, Jager N, Kool M, Zichner T, Hutter B, Sultan M, et al. Dissecting
the genomic complexity underlying medulloblastoma. Nature. 2012;
488(7409):100–5.
64. Xu J, Margol A, Asgharzadeh S, Erdreich-Epstein A. Pediatric brain tumor cell
lines. J Cell Biochem. 2015;116(2):218–24.
65. Milde T, Lodrini M, Savelyeva L, Korshunov A, Kool M, Brueckner LM, et al.
HD-MB03 is a novel Group 3 medulloblastoma model demonstrating
sensitivity to histone deacetylase inhibitor treatment. J Neuro-Oncol. 2012;
110(3):335–48.
66. Thompson EM, Whitney NL, Wu YJ, Neuwelt EA. The effect of alpha-v
integrin inhibition on the malignant characteristics of medulloblastoma.
J Neurosurg Pediatr. 2013;11(1):60–7.
67. Shu Q, Antalffy B, Su JM, Adesina A, Ou CN, Pietsch T, et al. Valproic Acid
prolongs survival time of severe combined immunodeficient mice bearing
intracerebellar orthotopic medulloblastoma xenografts. Clin Cancer Res.
2006;12(15):4687–94.
68. Mastronuzzi A, Miele E, Po A, Antonelli M, Buttarelli FR, Colafati GS, et al.
Large cell anaplastic medulloblastoma metastatic to the scalp: tumor and
derived stem-like cells features. BMC Cancer. 2014;14:262.
69. Trumpp A, Wiestler OD. Mechanisms of Disease: cancer stem cells–targeting
the evil twin. Nat Clin Pract Oncol. 2008;5(6):337–47.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Dietl et al. BMC Cancer  (2016) 16:115 Page 13 of 13
